by Michael Nevradakis, Ph.D., Childrens Health Defense:

During three days of meetings last week, advisers to the Centers for Disease Control and Prevention last week voted unanimously in favor of recommending Pfizer’s new 20-valent pneumococcal conjugate vaccine — currently administered only to adults — as an “option” for children.

Advisers to the Centers for Disease Control and Prevention (CDC) last week recommended newly approved vaccines for respiratory syncytial virus (RSV) — despite concerns about the efficacy and safety of the new vaccines, potentially harmful interactions with the flu and COVID-19 vaccines and the unspecified cost for the vaccines.